Hostname: page-component-848d4c4894-wzw2p Total loading time: 0 Render date: 2024-06-01T04:06:25.524Z Has data issue: false hasContentIssue false
  • English
  • Français

Drug disposition and switch process: an attractive hypothesis

Published online by Cambridge University Press:  16 April 2020

M Toutoungi  and
J Richard
M Toutoungi
Affiliation:
Department of Psychiatry of the University of Geneva, 10 Chemin du Petit Bel-Air, CH-1225, Chêne Bourg
J Richard
Affiliation:
Department of Geriatric Psychiatry of the University of Geneva, 10 Chemin du Petit Bel-Air, CH-1225, Chêne Bourg, Switzerland
Get access

Summary

Two cases of bipolar psychosis presented a rapid manic switch following administration of tricyclic antidepressants. In both cases the oxidation capacity was genetically deficient. The role of oxidation deficit is discussed in the pathogenesis of switch process and preventive measures are considered.

Keywords

imipramineclomipramineswitch processoxidation polymorphism
Type
Original article
Information
European Psychiatry , Volume 6 , Issue 1 , 1991 , pp. 53 - 55
Copyright
Copyright © Elsevier, Paris 1991

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Angst, J (1987) Switch from depression to mania, or from mania to depression: role of psychotropic drugs. Psychopharmacol Bull, 23, 66–67Google ScholarPubMed
Balant-Gorgia, A.E.Balant, LPGenet, CDayer, PAeschlimann, JMGarrone, G (1986) Importance of oxidative polymorphism and levomepromazine treatment on he steady-state blood concentrations of clomipramine and its major metabolites. Eur J Clin Pharmacol 31, 449–455CrossRefGoogle Scholar
Bertilson, LAberg-Wisted, A (1983) The debrisoquine hydroxylation test predict steady state plasma level of desipramine. Br J Clin Pharmacol 15, 388–390CrossRefGoogle Scholar
Breimer, DDAchellens, JHM (1990) A cocktail strategy to assess in vivo oxidative drug metabolism in humans. Trends Pharmacol Sci 11, 223–225CrossRefGoogle ScholarPubMed
Brosen, K (1990) Recent developments in hepatic drug oxidation; implication for clinical pharmacokinetics. Clin Pharmacokinet 18, 220–239CrossRefGoogle Scholar
Bunney, WE (1978) Psychopharmacology of the switch process in affective illness.In: Psychopharmacology: A generation of Progress (Lipton, MADiMascio, AKilam, KF eds) Raven Press; NY, 1249–1259Google Scholar
Editorial (1986) Akathisia and antispsychotic drugs. Lancet, ii, 1131–1132Google Scholar
Edwards, DJSorisio, DA (1988) Effect of imipramine on tyrosine and tryptophan are mediated by beta-adrenoreceptor stimulation. Life Sci 42, 853–862CrossRefGoogle Scholar
Eichelbaum, M (1984) Polymorphism drug oxidation in humans. Fed Proc 43, 2298–2303Google ScholarPubMed
Gabris, GBaumann, PJonzier-Perey, MBosshart, PWoggon, BKüpfer, A (1985) N-Methylation of maprotiline in debrisoquine/mephenitoin-phenotyped depressive patients. Biochem Pharmacol 34, 409-410CrossRefGoogle Scholar
Guengerich, FP (1989) Polymorphism of cytochrome P-450 in humans. Trends Pharmacol Sci 10, 107–109CrossRefGoogle ScholarPubMed
Küpfer, ASchmid, BPreisig, RPfaff, G (1984) Dextrometorphan as a safe probe for debrisoquine hydroxylation polymorphism. Lancet ii, 517–518CrossRefGoogle Scholar
Kupfer, DJCarpenter, LLFrank, E (1988) Possible role of antidepressants in precipitating mania and hypomania in recurrent depression. Am J Psychiatry 145, 804–808Google ScholarPubMed
Janowski, DSEl-Youssef, MKDavis, JMSekerke, HJ (1972) Cholinergic adrenergic hypothesis of mania and depression. Lancet ii, 632–635CrossRefGoogle Scholar
Meador-Woodruf, JH (1990) Psychiatric side effects of tricyclic antidepressants. Hosp Community Psychiatry 41, 84–86Google Scholar
Meador-Woodruf, JHAkil, MWisner-Carlson, RGrunhaus, L (1986) Behavioral and cognitive toxicity related to elevated plasma tricyclic antidepressant level. J Clin Psychopharmacol 8, 28–32Google Scholar
Mellström, BBertilson, LSäwe, JSchulz, MDSqövist, F (1981) E-and Z 10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation. Clin Pharmacol Ther 30, 189–193CrossRefGoogle Scholar
Mellström, BBertilson, LLou, YCSäwe, HSqövist, F (1983) Amitriptyline metabolism: relationship to polymorphic debrisoquine hydroxylation. Clin Pharmacol Ther 34, 516–520CrossRefGoogle ScholarPubMed
Preskorn, SHSimpson, S (1982) Tricyclic-antidepressant-induced delirium and plasma drug concentration. Am J Psychiatry 139, 822–823Google ScholarPubMed
Rubinstein, GMclntyre, IBurrows, GDNorman, TRMaguire, KP (1983) Metabolism of antidepressant drugs.In: Antidepressants (Burows, GDNorman, TRDavies, B eds) Elsevier, Amsterdam, 57–76Google Scholar
Sloan, TPMahjoub, ALancaster, RIdle, JRSmith, RL (1978) Polymorphism of carbon oxidation of drugs and clinical implications. Br Med J 2, 655-657CrossRefGoogle ScholarPubMed
Tissot, R (1975) The common pathophysiology of monoaminergic psychoses: a new hypothesis. Neuropsychobiology 1, 61–67CrossRefGoogle ScholarPubMed
Wachte, H (1990) The second-messenger dysbalance hypothesis of affective disorders. Pharmacopsychiatry 23, 27–32CrossRefGoogle Scholar
Wells, BGGelenberg, AJ (1981) Chemistry, pharmacology, pharmacokinetics, adverse effects, and efficacy of antidepressant maprotiline hydrochloride. Pharmacotherapy 1, 121–139CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.